GDF2 and cancer: Although a similar shift has not yet been identified in cancer, the recognition of a central role for type-II receptor utilization in regulating the balance between the pro- and anti-angiogenic effects of BMP9 highlights the value of a more nuanced understanding of BMP9 signaling in disease.